Parkinson's disease and colorectal cancer risk-A nested case control study

Cancer Epidemiology

Volumn 43, Issue , 2016, Pages 9-14

  Boursi, Ben ^a,b,c   Mamtani, Ronac ^a,b   Haynes, Kevin ^a   Yang, Yu Xiao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Age; Colorectal cancer; Dopamine; Microbiota; Parkinson's disease; Risk

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHILD; COLORECTAL CANCER; CONTROLLED STUDY; DATA BASE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; AGED; COHORT ANALYSIS; COLORECTAL NEOPLASMS; MIDDLE AGED; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RISK FACTORS;

EID: 84969590550     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2016.05.007     Document Type: Article

References (51)

1. de Lau L., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5(6):525-535.
2. Rodriguez-Oroz M.C., Jahanshahi M., Krack P., et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol. 2009, 8(12):1128-1139.
3. Ganguli M. Cancer and dementia, it's complicated. Alzheimer Dis. Assoc. Disord. 2015, 29(2):177-182.
4. Driver J.A., Logroscino G., Buring J.E., Gaziano J.M., Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol. Biomark. Prev. 2007, 16(6):1260-1265.
5. Benito-Leon J., Aleja J.G., Martinez-Salio A., Louis E.D., Lichtman J.H., Bermejo-Pareja F. Symptomatic atherosclerotic disease and decreased risk of cancer-specific mortality: a prospective, population-based study (NEDICES). Medicine 2015, 94(32):e1287.
6. Tabares-seisdedos R., Dumont N., Baudot A., et al. No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol. 2011, 12:604-608.
7. Rugbjerg K., Friis S., Lassen C.F., Ritz B., Olsen J.H. Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease. Int. J. Cancer 2012, 131(8):1904-1911.
8. Kareus S.A., Figueroa K.P., Cannon-Albright L.A., Pulst S.M. Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study. Arch. Neurol. 2012, 69(12):1572-1577.
9. Doshay L.J. Problem situations in the treatment of paralysis agitans. J. Am. Med. Assoc. 1954, 156(7):680-684.
10. Elbaz A., Peterson B.J., Yang P., et al. Nonfatal cancer preceding Parkinson's disease: a case-control study. Epidemiology 2002, 13(2):157-164.
11. Olsen J.H., Friis S., Frederiksen K., McLaughlin J.K., Mellemkjaer L., Møller H. Atypical cancer pattern in patients with Parkinson's disease. Br. J. Cancer 2005, 92(1):201-205.
12. Vanacore N., Spila-Alegiani S., Raschetti R., Meco G. Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 1999, 52(2):395-398.
13. Ong E.L., Goldacre R., Goldacre M. Differential risks of cancer types in people with Parkinson's disease: a national record-linkage study. Eur. J. Cancer 2014, 50(14):2456-2462.
14. Becker C., Brobert G.P., Johansson S., Jick S.S., Meier C.R. Cancer risk in association with Parkinson disease: a population-based study. Parkinsonism Relat. Disord. 2010, 16(3):186-190.
15. Bajaj A., Driver J.A., Schernhammer E.S. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010, 21(5):697-707.
16. Elbaz A., Peterson B.J., Bower J.H., et al. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study. Mov. Disord. 2005, 20(6):719-725.
17. Lin P.Y., Chang S.N., Hsiao T.H., Huang B.T., Lin C.H., Yang P.C. Association between Parkinson disease and risk of cancer in Taiwan. JAMA Oncol. 2015, 1(5):633-640.
18. Lo R.Y., Tanner C.M., Van Den Eeden S.K., Albers K.B., Leimpeter A.D., Nelson L.M. Comorbid cancer in Parkinson's disease. Mov. Disord. 2010, 25(12):1809-1817.
19. Ibanez K., Boullosa C., Tabares-Seisdedos R., Baudot A., Valencia A. Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses. PLoS Genet. 2014, 10(2):e1004173.
20. Agalliu I., San Luciano M., Mirelman A., et al. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. JAMA Neurol. 2015, 72(1):58-65.
21. Driver J.A. Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence. Biogerontology 2014, 15(6):547-557.
22. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29(1):15-32.
23. Schernhammer E., Chen H., Ritz B. Circulating melatonin levels: possible link between Parkinson's disease and cancer risk?. Cancer Causes Control 2006, 17(4):577-582.
24. Powers K.M., Smith-Weller T., Franklin G.M., Longstreth W.T., Swanson P.D., Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat. Disord. 2006, 12(3):185-189.
25. Rostami-Hodjegan A., Lennard M.S., Woods H.F., Tucker G.T. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 1998, 8(3):227-238.
26. Tan L.C., Methawasin K., Tan E.K., et al. Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese Health Study. J. Neurol. Neurosurg. Psychiatry 2015, 10.1136/jnnp-2014-310065.
27. Wang V., Chao T.H., Hsieh C.C., Lin C.C., Kao C.H. Cancer risks among the users of ergot-derived dopamine agonists for Parkinson's disease, a nationwide population-based survey. Parkinsonism Relat. Disord. 2015, 21(1):18-22.
28. Fasano A., Visanji N.P., Liu L., Lang A.E., Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2015, 14(6):625-639.
29. Gold A., Turkalp Z.T., Munoz D.G. Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease. Mov. Disord. 2013, 28(2):237-240.
30. Bottner M., Zorenkov D., Hellwig I., et al. Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol. Dis. 2012, 48(3):474-480.
31. Braak H., Rub U., Gai W.P., Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 2003, 110(5):517-536.
32. Wakabayashi K., Takahashi H., Takeda S., Ohama E., Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol. 1988, 76(3):217-221.
33. Lebouvier T., Neunlist M., Bruley des Varannes S., et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One 2010, 5(9):e12728. 1-9.
34. Keshavarzian A., Green S.J., Engen P.A., et al. Colonic bacterial composition in Parkinson's disease. Mov. Disord. 2015, 30(10):1351-1360.
35. Svensson E., Horvath-Puho E., Thomsen R.W., et al. Vagotomy and subsequent risk of Parkinson's disease. Ann. Neurol. 2015, 78(4):522-529.
36. Boursi B., Haynes K., Mamtani R., Yang Y.X. Impact of antibiotic exposure on the risk of colorectal cancer. Pharmacoepidemiol. Drug Saf. 2015 May, 24(5):534-542.
37. Boursi B., Mamtani R., Haynes K., Yang Y.X. Recurrent antibiotic exposure may promote cancer formation-another step in understanding the role of the human microbiota?. Eur. J. Cancer 2015, 9:805-809. pii: S0959-8049(15)00805-9. 10.1016/j.ejca.2015.08.015.
38. Schulz M.D., Atay C., Heringer J., et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. Nature 2014, 514(7523):508-512.
39. Boursi B., Haynes K., Mamtani R., Yang Y.X. Impact of antibiotic exposure on the risk of colorectal cancer. Pharmacoepidemiol. Drug Saf. 2015, 24(5):534-542.
40. Maguire A., Blak B.T., Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol. Drug Saf. 2009, 18:76-83.
41. Bourke A., Dattani H., Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform. Prim. Care 2004, 12:171-177.
42. Lewis J.D., Schinnar R., Bilker W.B., Wang X., Strom B.L. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol. Drug Saf. 2007, 16:393-401.
43. Hollowell J. The general practice research database: quality of morbidity data. Popul. Trends 1997, 87:36-40.
44. Lewis J.D., Bilker W.B., Weinstein R.B., Strom B.L. The relationship between time since registration and measured incidence rates in the general practice research database. Pharmacoepidemiol. Drug Saf. 2005, 14:443-451.
45. Haynes K., Forde K.A., Schinnar R., et al. Cancer incidence in The Health Improvement Network. Pharmacoepidemiol. Drug Saf. 2009, 18:730-736.
46. Chisholm J. The Read clinical classification. BMJ 1990, 300:1092.
47. Benson T. The history of the Read Codes: the inaugural James Read Memorial Lecture 2011. Inform. Prim. Care 2011, 19:173-182.
48. Lubin J.H., Gail M.H. Biased selection of controls for case-control analysis of cohort studies. Biometrics 1984, 40:63-75.
49. Mayeux R., Marder K., Cote L.J., et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern manhattan, 1988-1993. Am. J. Epidemiol. 1995, 142(8):820-827.
50. Sarkar C., Chakroborty D., Dasgupta P.S., Basu S. Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. Int. J. Cancer 2015, 137(3):744-749.
51. Leranth C., Roth R.H., Elsworth J.D., Naftolin F., Horvath T.L., Redmond D.E. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J. Neurosci. 2000, 20(23):8604-8609.